AdAlta (ASX:1AD) is the pioneer of a novel technology platform that mimics the shape and engineers key stability features of the antigen binding domain of shark antibodies into human proteins to create unique compounds, known as i-bodies, for therapeutic intervention in disease. AdAlta is utilising the power of its i-body technology platform to develop a pipeline of i-bodies (drugs), with an initial focus on treating fibrotic diseases.